Projects funded by the NCN

Information on the principal investigator and host institution

Information of the project and the call

Keywords

Equipment

Delete all

Search results

41 projects found matching your search criteria :

  1. Essential oils, propolis and nanoparticles of silver and copper as an alternative or supporting agent for conventional t...

    Call: PRELUDIUM 8 , Panel: NZ7

    Principal investigator: Katarzyna Gucwa

    Politechnika Gdańska, Wydział Chemiczny

  2. DNA repair pathways contributing to resistance to photodynamic therapy and as possible theraupeutic targets

    Call: OPUS 8 , Panel: NZ5

    Principal investigator: dr hab. Elżbieta Speina

    Instytut Biochemii i Biofizyki PAN

  3. Role of the selected anti-tumor agents transported by electropermeabilization to the drug-sensitive and drug-resistant c...

    Call: PRELUDIUM 8 , Panel: NZ7

    Principal investigator: dr Joanna Weżgowiec

    Politechnika Wrocławska, Wydział Podstawowych Problemów Techniki

  4. The influence of bone marrow microenvironment on the regulation of BRCA1 mRNA translation in leukemia cells; role in the...

    Call: SONATA 8 , Panel: NZ3

    Principal investigator: dr Paulina Podszywałow-Bartnicka

    Instytut Biologii Doświadczalnej im. M. Nenckiego PAN

  5. Identification of new, clinically relevant genetic and epigenetic aberrations by next-generation sequencing in chronic m...

    Call: HARMONIA 6 , Panel: NZ5

    Principal investigator: dr Tomasz Stokłosa

    Warszawski Uniwersytet Medyczny, Wydział Lekarski

  6. Immunological biomarkers of drug resistant epilepsy and response to immunomodulatory therapy with ACTH in children

    Call: PRELUDIUM 6 , Panel: NZ4

    Principal investigator: Magdalena Kaczorowska-Frontczak

    Instytut "Pomnik - Centrum Zdrowia Dziecka"

  7. New drug carriers in targeted anticancer therapy

    Call: OPUS 1 , Panel: ST5

    Principal investigator: prof. Artur Terzyk

    Uniwersytet Mikołaja Kopernika, Wydział Chemii

  8. "One step to game changer": combined antimicrobial therapy based on AI and nanotechnology to combat challenging diabetes...

    Call: SONATA 19 , Panel: NZ7

    Principal investigator: dr Barbara Pucelik

    Sieć Badawcza Łukasiewicz – Krakowski Instytut Technologiczny

  9. Extensive analysis of the immunological profile of pediatric patients with acute lymphoblastic leukemia in order to iden...

    Call: PRELUDIUM 22 , Panel: NZ5

    Principal investigator: Anna Krętowska-Grunwald

    Uniwersytet Medyczny w Białymstoku

  10. Unlocking nature's potential - exploring the ability of newly isolated from the environment bacteriophage and its enzyme...

    Call: PRELUDIUM 22 , Panel: NZ9

    Principal investigator: Aleksandra Łukasiak

    Uniwersytet Gdański, Wydział Biologii

  11. Cuproptosis, a novel pathway of regulated cell death as a therapeutic target in treatment-naïve and targeted therapy-res...

    Call: OPUS 25 , Panel: NZ5

    Principal investigator: dr hab. Mariusz Hartman

    Uniwersytet Medyczny w Łodzi, Wydział Lekarski

  12. Unveiling the molecular signature underlying resistance to CD19 CAR-T therapy in malignant cells.

    Call: PRELUDIUM 22 , Panel: NZ7

    Principal investigator: Marta Krawczyk

    Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego Polskiej Akademii Nauk

  13. Targeted poloxamer micelles with selected drugs as a strategy for overcoming the mechanisms of multidrug resistance in p...

    Call: PRELUDIUM BIS 4 , Panel: NZ7

    Principal investigator: prof. Tomasz Gośliński

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  14. Three-phase drug carriers - design towards a prolonged release, development of a transport model and its verification. C...

    Call: PRELUDIUM BIS 4 , Panel: ST8

    Principal investigator: prof. Anna Trusek

    Politechnika Wrocławska

  15. Design and implementation of effective cOmbination of Phages and Antibiotics for improved TheRApy protocols against KLEb...

    Call: JPIAMR ACTION Call 2022 , Panel: NZ6

    Principal investigator: prof. Zuzanna Drulis-Kawa

    Uniwersytet Wrocławski

  16. The use of genetic analysis of liquid biopsy for predicting and monitoring ofresponse to therapies and tumor evolution i...

    Call: OPUS 22 , Panel: NZ7

    Principal investigator: dr Magdalena Olbryt

    Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy, Oddział w Gliwicach

  17. Inhibiting the Mitochondrial Intermembrane Space Assembly pathway as a newapproach to prevent metabolic reprogramming of...

    Call: OPUS 22 , Panel: NZ5

    Principal investigator: dr hab. Carlo Vascotto

    Instytut Hematologii i Transfuzjologii

  18. Development of phage-based tool with the potential to treat antibiotic-resistant gonorrhea

    Call: PRELUDIUM BIS 3 , Panel: NZ6

    Principal investigator: dr hab. Monika Adamczyk-Popławska

    Uniwersytet Warszawski, Wydział Biologii

  19. RE-SENSE: Dual-loaded lipid nanoparticles to overcome the resistance of non-small cell lung cancer cells to personalized...

    Call: PRELUDIUM 20 , Panel: NZ7

    Principal investigator: Mikołaj Czajkowski

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  20. In search for molecular targets to overcome doxorubicin resistance in triple-negative breast cancer with the use of inno...

    Call: PRELUDIUM 20 , Panel: NZ7

    Principal investigator: Anna Pogorzelska

    Narodowy Instytut Leków

  21. Reversible senescence as a new mechanism of cancer cell resistance for chemotherapy. Analysis of the mechanism of cancer...

    Call: SONATINA 5 , Panel: NZ3

    Principal investigator: dr Karolina Staniak

    Politechnika Warszawska, Wydział Chemiczny

  22. FGF/FGFR-signalling in mediation of resistance to therapy in triple-positive breast cancer: clinical implications of PAM...

    Call: OPUS 20 , Panel: NZ4

    Principal investigator: dr hab. Hanna Romańska-Knight

    Uniwersytet Medyczny w Łodzi, Wydział Lekarski

  23. Dual CBR1-AKR1C3 inhibitors as a new approach to improve effectiveness and safety of anthracycline therapy.

    Call: PRELUDIUM 19 , Panel: NZ7

    Principal investigator: Marek Jamrozik

    Uniwersytet Jagielloński, Collegium Medicum

  24. Cell adhesion molecules as regulators of tunneling nanotubes (TNTs) formation and protein transfer in leukemia microenvi...

    Call: PRELUDIUM BIS 1 , Panel: NZ3

    Principal investigator: dr hab. Katarzyna Piwocka

    Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polskiej Akademii Nauk

  25. The use of olaparib and ATR / CHK1 kinase inhibitors as a targeted anti-cancer therapy based on synthetic lethality

    Call: SONATA BIS 9 , Panel: NZ7

    Principal investigator: dr hab. Aneta Rogalska

    Uniwersytet Łódzki, Wydział Biologii i Ochrony Środowiska

  26. The significance of cancer specific PFK-II (PFKFB3 and PFKFB4) isoenzymes inhibition in overcoming resistance to BRAF in...

    Call: PRELUDIUM 16 , Panel: NZ5

    Principal investigator: Sonia Trojan

    Uniwersytet Jagielloński - Collegium Medicum, Collegium Medicum, Wydział Lekarski

  27. The combination of radiotherapy with imiquimod and sunitinib as a new therapeutic strategy overcoming some of the tumor ...

    Call: SONATA 14 , Panel: NZ5

    Principal investigator: dr Magdalena Jarosz-Biej

    Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy, Oddział w Gliwicach

  28. Role of RNA binding proteins in resistance to therapy of leukemia cells in bone marrow niche

    Call: HARMONIA 10 , Panel: NZ3

    Principal investigator: dr Paulina Podszywałow-Bartnicka

    Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polskiej Akademii Nauk

  29. Tunneling nanotubes (TNTs) within the leukemia microenvironment; influence of metabolic remodeling and implications for ...

    Call: OPUS 15 , Panel: NZ3

    Principal investigator: dr hab. Katarzyna Piwocka

    Instytut Biologii Doświadczalnej im. M. Nenckiego Polskiej Akademii Nauk

  30. Regulation of epithelial to mesenchymal transition and therapy resistance to antitumor therapies by MCPIP1

    Call: SONATA BIS 7 , Panel: NZ5

    Principal investigator: dr hab. Katarzyna Miękus

    Uniwersytet Jagielloński, Wydział Biochemii, Biofizyki i Biotechnologii

  31. Molecular and pharmacological approaches based on inhibition of glycolysis to overcome de novo- and antiangiogenic thera...

    Call: OPUS 13 , Panel: NZ3

    Principal investigator: dr hab. Beata Pająk

    Wojskowy Instytut Higieny i Epidemiologii im. gen. Karola Kaczkowskiego

  32. Nano-phages - potential agents in an innovative therapy of bacterial infections

    Call: OPUS 12 , Panel: NZ6

    Principal investigator: dr Piotr Golec

    Uniwersytet Gdański, Wydział Biologii

  33. Identification and targeting molecular drug resistance mechanisms in adult B-cell acute lymphoblastic leukemia

    Call: OPUS 1 , Panel: NZ4

    Principal investigator: dr hab. Przemysław Juszczyński

    Instytut Hematologii i Transfuzjologii

  34. Fabrication of new photosensitive nanocomposites based on graphite oxide and their interaction with microorganisms which...

    Call: OPUS 12 , Panel: ST5

    Principal investigator: dr Anna Łukowiak

    Instytut Niskich Temperatur i Badań Strukturalnych im. Włodzimierza Trzebiatowskiego Polskiej Akademii Nauk

  35. Role of Prolactin-Induced Protein (PIP) in breast cancer progression using an adjuvant therapy.

    Call: OPUS 12 , Panel: NZ5

    Principal investigator: prof. Piotr Dzięgiel

    Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu, Wydział Lekarski

  36. Nanoencapsulated Photosensitizing Drugs for Photodynamic Therapy of Resistant Cancers and Microbes

    Call: SONATA BIS 6 , Panel: NZ7

    Principal investigator: dr Janusz Dąbrowski

    Uniwersytet Jagielloński, Wydział Chemii

  37. Old drugs - new perspectives: modulation of antibiotics activity by caffeine and pentoxifylline

    Call: SONATA 11 , Panel: NZ7

    Principal investigator: dr Anna Woziwodzka

    Uniwersytet Gdański, Międzyuczelniany Wydział Biotechnologii Uniwersytetu Gdańskiego i Gdańskiego Uniwersytetu Medycznego

  38. Characterization and improvement of anti-cancer properties of second generation antagonists of Mdm2 oncoprotein

    Call: SONATA 11 , Panel: NZ7

    Principal investigator: dr Łukasz Skalniak

    Uniwersytet Jagielloński, Wydział Chemii

  39. Phosphorylation of translation initiation factor eIF2alpha as regulator of synthesis of proinflammatory and signaling cy...

    Call: PRELUDIUM 10 , Panel: NZ3

    Principal investigator: Wioleta Dudka-Ruszkowska

    Instytut Biologii Doświadczalnej im. M. Nenckiego Polskiej Akademii Nauk

  40. Immunomodulatory properties of nanosystems containing membrane-active compounds and their potential in therapy of drug r...

    Call: PRELUDIUM 10 , Panel: NZ6

    Principal investigator: Ewelina Piktel

    Uniwersytet Medyczny w Białymstoku, Wydział Lekarski z Oddziałem Stomatologii i Oddziałem Nauczania w Języku Angielskim

  41. Protein and gene expression analysis in the course of renal cancer stem-like cells' primary resistance to sorafenib in h...

    Call: PRELUDIUM 9 , Panel: NZ5

    Principal investigator: Zofia Bielecka

    Wojskowy Instytut Medyczny

O Narodowym Centrum Nauki

Finansowanie nauki

Współpraca zagraniczna

Centrum prasowe

Deklaracja dostępności
Przetwarzanie danych osobowych
Polityka cookies

Partnerzy